Related Experiment Video
Updated: Sep 19, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Merkel Cell Carcinoma: Current Treatment Landscape and Emerging Therapeutic Targets
Kelly Pan1, A Maria Vromans1, Liang Cheng2
1Department of Internal Medicine, Brown University Health, Providence, RI, USA.
Merkel cell carcinoma (MCC), an aggressive skin cancer, is often diagnosed late. Current treatments include surgery for local disease and immunotherapy for advanced stages, with new therapies in development.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer.
- It is primarily caused by Merkel cell polyomavirus (MCPyV) and UV radiation.
- Delayed diagnosis due to subtle presentation leads to advanced-stage detection and poor prognoses.
Purpose of the Study:
- To review diagnostic workup for MCC.
- To examine prognostic markers in MCC.
- To discuss current and emerging MCC treatments.
Main Methods:
- Literature review of diagnostic approaches.
- Analysis of prognostic indicators.
- Synthesis of current therapeutic modalities.
- Evaluation of ongoing clinical trials for novel therapies.
Main Results:
- Surgical resection with adjuvant radiation is standard for local MCC.
- PD-1/PD-L1 inhibitors are the standard of care for advanced or unresectable MCC.
- Numerous clinical trials are investigating novel immunotherapies, targeted treatments, and vaccines for advanced or recurrent MCC.
Conclusions:
- MCC is an aggressive malignancy with a rapidly evolving treatment landscape.
- Emerging therapies show promise for improving outcomes in advanced MCC.
- Continued research is crucial for enhancing patient prognosis.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

